CytomX Therapeutics, Inc. (CTMX)
2.03
-0.02
(-0.98%)
USD |
NASDAQ |
Nov 20, 16:00
2.05
+0.02
(+0.99%)
After-Hours: 20:00
CytomX Therapeutics Enterprise Value : 97.94M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | 97.94M |
| November 19, 2026 | 102.29M |
| November 18, 2026 | 65.24M |
| November 17, 2026 | 78.32M |
| November 16, 2026 | 88.13M |
| November 13, 2026 | 100.12M |
| November 12, 2026 | 100.12M |
| November 11, 2026 | 119.73M |
| November 10, 2026 | 87.04M |
| November 09, 2026 | 87.04M |
| November 06, 2026 | 132.81M |
| November 05, 2026 | 121.91M |
| November 04, 2026 | 167.68M |
| November 03, 2026 | 130.63M |
| November 02, 2026 | 141.53M |
| October 30, 2026 | 165.50M |
| October 29, 2026 | 154.60M |
| October 28, 2026 | 169.86M |
| October 27, 2026 | 158.96M |
| October 26, 2026 | 140.44M |
| October 23, 2026 | 161.14M |
| October 22, 2026 | 187.30M |
| October 21, 2026 | 178.58M |
| October 20, 2026 | 202.55M |
| October 19, 2026 | 165.50M |
| Date | Value |
|---|---|
| October 16, 2026 | 152.42M |
| October 15, 2026 | 180.76M |
| October 14, 2026 | 141.53M |
| October 13, 2026 | 162.23M |
| October 12, 2026 | 182.94M |
| October 09, 2026 | 215.63M |
| October 08, 2026 | 193.83M |
| October 07, 2026 | 211.27M |
| October 06, 2026 | 213.45M |
| October 05, 2026 | 217.81M |
| October 02, 2026 | 213.45M |
| October 01, 2026 | 228.71M |
| September 30, 2026 | 248.32M |
| September 29, 2026 | 273.73M |
| September 28, 2026 | 260.66M |
| September 25, 2026 | 262.84M |
| September 24, 2026 | 273.73M |
| September 23, 2026 | 280.27M |
| September 22, 2026 | 315.13M |
| September 21, 2026 | 275.91M |
| September 18, 2026 | 275.91M |
| September 17, 2026 | 288.98M |
| September 16, 2026 | 277.00M |
| September 15, 2026 | 260.66M |
| September 14, 2026 | 371.78M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals, Inc. | 88.59B |
| Arcturus Therapeutics Holdings, Inc. | 49.08M |
| Corvus Pharmaceuticals, Inc. | 613.05M |
| ACADIA Pharmaceuticals, Inc. | 2.052B |
| Alnylam Pharmaceuticals, Inc. | 18.66B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.00M |
| Revenue (Quarterly) | 1.688M |
| Total Expenses (Quarterly) | 21.69M |
| EPS Diluted (Quarterly) | -0.0913 |
| Gross Profit Margin (Quarterly) | 75.41% |
| Profit Margin (Quarterly) | -1.18K% |
| Earnings Yield | -22.76% |
| Normalized Earnings Yield | -22.76 |